Alder Biopharmaceuticals Inc., of Bothell, Wash., said researchers will present findings from a randomized, double-blind, placebo-controlled proof-of-concept trial of lead compound ALD403 in preventing frequent episodic migraine at the American Academy of Neurology meeting in Philadelphia next month.